Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367528 | 0.91 | TP53 (0.41) | SMN1; SMN2LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL10070053 | 0.90 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL15101330 | 0.88 | ENPP2 (0.38) | SMN1; SMN2LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL10070403 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL10069922 | 0.87 | ENPP2 (0.39) | SMN1; SMN2LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL10071007 | 0.86 | ENPP2 (0.39) | SMN1; SMN2LMNAMAPTMEN1CYP2C19 | |
| SCHEMBL15101651 | 0.86 | TLR9 (0.36) | SMN1; SMN2LMNAMAPTP2RX7 | |
| SCHEMBL10070927 | 0.84 | TP53 (0.39) | SMN1; SMN2LMNAKMT2ATP53CNR2 | |
| SCHEMBL12894073 | 0.82 | KDM4E (0.33) | SMN1; SMN2LMNAMAPTHTTTP53 | |
| SCHEMBL367968 | 0.81 | TP53 (0.42) | SMN1; SMN2LMNAMAPTMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | SMN1; SMN2 2192/4885LMNA 4293/4885MAPT 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.